NTR 2.0: a rationally engineered prodrug-converting enzyme with substantially enhanced efficacy for targeted cell ablation
Year: 2022
Type: article
Source: Nature Methods
Authors: Abigail V. Sharrock, Timothy S. Mulligan, Kelsi R. Hall, Elsie M. Williams, David T. White, Liyun Zhang, Kevin Emmerich, Frazer Matthews, Saumya Nimmagadda, Selena Washington, Katherine D. Le, Danielle Meir-Levi, Olivia L. Cox, Meera T. Saxena, Anne L. Calof, Martha E. Lopez-Burks, Arthur D. Lander, Ding Ding, Hongkai Ji, David F. Ackerley, Jeff S. Mumm
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funders: U.S. Department of Health and Human Services, Ministry of Health, New Zealand, National Institutes of Health, Health Research Council of New Zealand, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, NIH Office of the Director, National Eye Institute, National Institute of Neurological Disorders and Stroke, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Investigating the multifactorial origins of congenital heart disease, G2054683030, G2155858550, Big Data Methods for Decoding Gene Regulation, Targeted Cellular Ablation in Transgenic Zebrafish, G336228438, G4264833860, Spatial Dynamics of Tissue and Organ Size Control, Improved Animal Models for Cell-Specific Regenerative Medicine Paradigms, G4724894964, Multiscale Models of Wound Cell Plasticity for Regeneration, G51532674, G5508197105, P30 Wilmer Core Grant for Vision Research, Identification of Cellular, Molecular and Genetic Factors Regulating RGC Regeneration, G673135514, Robotic whole organism HTS platform for drug discovery and development, G828272606, Visual Science Training Program
OpenAlex ID: W4220893419